Pretransplant IFN-γ ELISPOT assay as a potential screening test to select immunosuppression protocols for patients receiving basiliximab induction therapy

Translational Research

Volumn 160, Issue 3, 2012, Pages 230-236

  Kim, Yonggoo ^a   Park, Ki Hyun ^b   Chung, Byung Ha ^a   Choi, Bum Soon ^a   Yang, Chul Woo ^a   Kim, Ji Il ^a   Moon, In Sung ^a   Park, Yeon Joon ^a   Han, Kyungja ^a   Oh, Eun Jee ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE PERIOD; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; STEROID THERAPY;

EID: 84865714930     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2012.02.009     Document Type: Article

References (27)

1. P.S. Heeger, N.S. Greenspan, and S. Kuhlenschmidt Pretransplant frequency of donor-specific, IFN-γ-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of post-transplant rejection episodes J Immunol 163 1999 2267 2275 (Pubitemid 29382237)
2. B.S. Gebauer, D.E. Hricik, and A. Atallah Evolution of the enzyme linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool Am J Transplant 2 2002 857 866 (Pubitemid 36306841)
3. J.J. Augustine, D.S. Siu, and M.J. Clemente Pre-transplant IFN-γ ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients Am J Transplant 5 2005 1971 1975 (Pubitemid 41039873)
4. E.D. Poggio, M. Clemente, and D.E. Hricik Panel of reactive T cells as a measurement of primed cellular alloimmunity in kidney transplant candidates J Am Soc Nephrol 17 2006 564 572
5. P.S. Heeger T-cell allorecognition and transplant rejection: a summary and update Am J Transplant 3 2003 525 533 (Pubitemid 36612835)
6. J.J. Augustine, E.D. Poggio, P.S. Heeger, and D.E. Hricik Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots Transplantation 86 2008 529 534
7. N.L. Reinsmoen, K.M. Cornett, and R. Kloehn Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection Transplantation 85 2008 462 470
8. B. Nashan, R. Moore, and P. Amlot Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group Lancet 350 1997 1193 1198 (Pubitemid 127445091)
9. B.D. Kahan, P.R. Rajagopalan, and M. Hall Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group Transplantation 67 1999 276 284 (Pubitemid 29066355)
10. J. Sageshima, G. Ciancio, L. Chen, and G.W. Burke III Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation Biologics 3 2009 319 336
11. P. Salis, C. Caccamo, R. Verzaro, S. Gruttadauria, and M. Artero The role of basiliximab in the evolving renal transplantation immunosuppression protocol Biologics 2 2008 175 188
12. D.C. Brennan, J.A. Daller, and K.D. Lake Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation N Engl J Med 355 2006 1967 1977 (Pubitemid 44708016)
13. Y. Kim, C.W. Yang, and I.S. Moon Donor-specific HLA class I and CREG antibodies in complement-dependent cytotoxicity-negative renal transplants Ann Clin Lab Sci 40 2010 330 335
14. S. Jung, E.J. Oh, and C.W. Yang Comparative evaluation of ELISA and Luminex panel reactive antibody assays for HLA alloantibody screening Korean J Lab Med 29 2009 473 480
15. A.S. Levey, J.P. Bosch, and J.B. Lewis A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
16. S.H. Kim, E.J. Oh, and M.J. Kim Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients Transplant Proc 39 2007 3057 3060 (Pubitemid 350251446)
17. F. Vincenti, R. Kirkman, and S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group N Engl J Med 338 1998 161 165 (Pubitemid 28041863)
18. J. Radermacher, M. Meiners, and C. Bramlage Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506 Transpl Int 11 1998 3 10 (Pubitemid 28112402)
19. J.D. Pirsch, J. Miller, and M.H. Deierhoi A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group Transplantation 63 1997 977 983 (Pubitemid 27173021)
20. R. Margreiter Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study Lancet 359 2002 741 746 (Pubitemid 34215073)
21. A.D. Mayer, J. Dmitrewski, and J.P. Squifflet Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group Transplantation 64 1997 436 443 (Pubitemid 27349884)
22. F. Vincenti, S. Friman, and E. Scheuermann Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus Am J Transplant 7 2007 1506 1514 (Pubitemid 46776239)
23. G. Opelz, and B. Dohler Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation Transplantation 87 2009 795 802
24. C. Sommerer, M. Zeier, S. Meuer, and T. Giese Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients Transplantation 89 2010 1417 1423
25. W.Y. Almawi, and O.K. Melemedjian Clinical and mechanistic differences between FK506 (tacrolimus) and cyclosporin A Nephrol Dial Transplant 15 2000 1916 1918
26. J.M. Halimi, M. Buchler, and A. Al Najjar Urinary albumin excretion and the risk of graft loss and death in proteinuric and nonproteinuric renal transplant recipients Am J Transplant 7 2007 618 625 (Pubitemid 46376448)
27. F.L. Nauta, S.J. Bakker, and W. van Oeveren Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients Am J Kidney Dis 57 2011 733 743